Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
VSPharmTech Co.,Ltd.
Study ID
NCT06959082
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Head and Neck Cancer Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VS-101 — DRUG
    VS-101
  • Cisplatin — DRUG
    Cisplatin
  • Radiation — RADIATION
    Radiation

Study Details

This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.

Key Dates

Start date
Mar 31, 2026
Status verified
Mar 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 2 mg of VS-101 + CRT
    2 mg of VS-101 + CRT
  • Experimental: 5 mg of VS-101 + CRT
    5 mg of VS-101 + CRT
  • Placebo Comparator: Only CRT
    Only CRT

Primary Outcome Measure

Disease control rate (DCR) [ Time Frame: 6 months and 12 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Yale Cancer CenterNew HavenConnecticut06510
Clinical Research Coordinator
[email protected]
203-228-2385
Cancer Center of KansasWichitaKansas67214
Study Coordinator
[email protected]
316-262-4467
NYU Langone HealthManhattanNew York10016
CRA
[email protected]
+82 1076270105

Find similar trials in New Haven, CT

By research site
Yale Cancer Center· New Haven, CTCancer Center of Kansas· Wichita, KSNYU Langone Health· Manhattan, NY

Related Studies